Stay updated on KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer

Sign up to get notified when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.
Latest website image capture
Clouds background image

Latest updates to the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T19:38:07.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The webpage has undergone significant changes, including the removal of detailed information about a Phase 1b study on combination chemo-immunotherapy for metastatic endocrine-resistant breast cancer, while adding a new study identifier and a revision number. The core content regarding the study's methodology and patient eligibility criteria has been largely deleted.
    Difference
    54%
    Check dated 2025-04-16T13:21:35.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T06:47:22.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T22:53:10.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.9%
    Check dated 2025-02-24T20:26:31.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.9%
    Check dated 2025-02-10T09:36:47.000Z thumbnail image

Stay in the know with updates to KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer

Enter your email address, and we'll notify you when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.